All In Biotech

NDA 208944 · Supernus Pharms

Gocovri

Amantadine Hydrochloride · Oral · Influenza A M2 Protein Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 24, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

324

86 Phase 3, 21 recruiting

FAERS reports

15,734

9,513 serious, 1,674 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications ( 1 ) As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes ( 1 )

Mechanism: The mechanism by which amantadine exerts efficacy in the treatment of dyskinesia in patients with Parkinson's disease or as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes is unknown. Amantadine is a weak uncompetitive antagonist of the NMDA receptor. Amantadine has not been shown to possess direct anticholinergic activity in animal studies; however, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation in humans. Amantadine may have direct and indirect effects on dopamine neurons; it...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • GOCOVRI · AMANTADINE HYDROCHLORIDE EQ 137MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • GOCOVRI · AMANTADINE HYDROCHLORIDE EQ 68.5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amantadine" as an intervention, any sponsor and status, largest first.

All 324 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall1,821
  • hallucination1,356
  • drug ineffective1,295
  • fatigue1,118
  • dyskinesia1,114
  • dizziness962
  • gait disturbance922
  • death898
  • tremor819
  • nausea694
  • parkinson^s disease678
  • asthenia663

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
2005113
20063
20076
200824
200941
201095
201137
2012148
2013406
2014475
2015643
2016888
20171,095
20181,455
20191,436
20201,599
20211,593
20221,471
2023959
20241,055
20251,223
2026952

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gocovri (Amantadine HCl)

2024 spending

$99.8M

Beneficiaries

4,906

30,705 claims

Per beneficiary

$20,351

$55.42 per unit

View as table
YearSpending
2020$53,349,153
2021$70,562,668
2022$82,318,372
2023$91,875,721
2024$99,842,782

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 616 on PubMed

Sponsor: Supernus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.